sanofi
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects
Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II
Asthma, Amlitelimab, Kymab, sanofi, Immunology
Sanofi backs $90M financing for I&I biologic developer
sanofi, Series, financing characteristics, II
Sanofi tempers its OX40 expectations in asthma after mid-stage miss
Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations
Sanofi adds new inflammatory target to growing Nurix tie-up
Nurix, sanofi, Target, STAT6 protein, human, cellular targeting, Collaboration, Inflammation, Autoimmune Diseases, TRANSCRIPTION FACTOR, DEL-AI
Sanofi and Johnson & Johnson’s E. coli Vaccine Candidate Fails in Phase 3 Trial
E. coli vaccine, Sanofi, Johnson & Johnson, Phase 3 trial failure, invasive E. coli disease, ExPEC9V
Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge
Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation
Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market
Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus
Sanofi Assures No Supply Disruptions Following FDA Warning Letter for US Manufacturing Site
Sanofi, FDA warning letter, US manufacturing site, supply interruptions, CGMP deviations
Pharmaceutical CEOs Emphasize Transparency to Counter Anti-Vaccine Sentiment in the US
Anti-vaccine movement, Transparency, GSK, Sanofi, Vaccine hesitancy, Public health